Hsa_circ_0000190 Promotes NSCLC Cell Resistance to Cisplatin via the Modulation of the miR-1253/IL-6 Axis

Table 1

Relationship between hsa_circ_0000190 and clinicopathological data of NSCLC patients.

Clinical feature	Low hsa_circ_0000190	High hsa_circ_0000190	P
Age (years)			0.241
<55	25	21
≥55	43	47
Sex			0.185
Male	35	37
Female	33	31
TNM stage			<0.05
I–II	45	20
III–IV	23	48
Tumor size			<0.05
<5 cm	42	21
≥5 cm	26	47
Metastasis			0.091
No	33	31
Yes	35	37